New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - aciclovir 25 mg/ml;   - solution for infusion - 25 mg/ml - active: aciclovir 25 mg/ml   excipient: hydrochloric acid sodium hydroxide - q.s. to ph nitrogen sodium hydroxide water for injection - - treatment of herpes simplex infections. - prophylaxis of herpes simplex infections in immune-compromised patients. - treatment of varicella zoster infections. - the treatment of herpes simplex infections in the neonate. - prophylaxis of cmv infection in bone marrow transplant recipients. it has been shown that high dose intravenous aciclovir reduces the incidence and delays the onset of cmv infection. when high dose intravenous aciclovir is followed by 6 months treatment with high dose oral aciclovir (see prescribing information for oral aciclovir) mortality and the incidence of viraemia are also reduced.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - aciclovir 25 mg/ml;   - solution for injection - 25 mg/ml - active: aciclovir 25 mg/ml   excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - aciclovir 25 mg/ml - solution for infusion - 25 mg/ml - active: aciclovir 25 mg/ml excipient: sodium hydroxide water for injection - dbl aciclovir intravenous infusion is indicated for: - treatment of herpes simplex infections. - prophylaxis of herpes simplex infections in immune-compromised patients. - treatment of varicella zoster infections. - the treatment of herpes simplex infections in the neonate. - prophylaxis of cmv infection in bone marrow transplant recipients. it has been shown that high dose intravenous aciclovir reduces the incidence and delays the onset of cmv infection. when high dose intravenous aciclovir is followed by 6 months treatment with high dose oral aciclovir (see prescribing information for oral aciclovir) mortality and the incidence of viraemia are also reduced.

Ireland - English - HPRA (Health Products Regulatory Authority)

hospira uk limited - aciclovir sodium - concentrate for soln for inf - 25 mg/ml - nucleosides and nucleotides excl. reverse transcriptase inhibitors

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valaciclovir hydrochloride, quantity: 556 mg (equivalent: valaciclovir, qty 500 mg) - tablet, film coated - excipient ingredients: povidone; crospovidone; colloidal anhydrous silica; carnauba wax; magnesium stearate; microcrystalline cellulose; colour - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. for the treatment of ophthalmic zoster. for the treatment of recurrent herpes labialis (cold sores) for the treatment of clinical episodes of genital herpes simplex infections. for the prevention of recurrent genital herpes. reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valtrex, it is recommended that patients use safer sex practices. (see precautions). prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

hospira benelux bv-srl - aciclovir sodium - eq. aciclovir 25 mg/ml - concentrate for solution for infusion - 25 mg/ml - aciclovir sodium - aciclovir

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

hospira benelux bv-srl - aciclovir sodium - eq. aciclovir 25 mg/ml - concentrate for solution for infusion - 25 mg/ml - aciclovir sodium - aciclovir

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

hospira benelux bv-srl - aciclovir sodium - eq. aciclovir 25 mg/ml - concentrate for solution for infusion - 25 mg/ml - aciclovir sodium - aciclovir

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - aciclovir, quantity: 800 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica - arx-aciclovir tablets are indicated for use in adult patients for: (1) the treatment of first episode (primary or non-primary) genital herpes and the management of recurrent episodes of genital herpes in certain patients. (2) the treatment of acute attacks of herpes zoster (shingles) when the duration of rash is less than 72 hours. (3) the management of patients with advaned symptomatic hiv disease cd4 + counts < 150 x 10(6)/l). in accordance with details specified in the "indications" and the "dosage and administration" sections of the approved product information provided as attachment 1.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - aciclovir, quantity: 200 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica - arx-aciclovir tablets are indicated for use in adult patients for: (1) the treatment of first episode (primary or non-primary) genital herpes and the management of recurrent episodes of genital herpes in certain patients. (2) the treatment of acute attacks of herpes zoster (shingles) when the duration of rash is less than 72 hours. (3) the management of patients with advanced symptomatic hiv disease (cd4 + counts < 150 x 10(6)/l). in accordance with details specified in the "indications" and the "dosage and adminsitration" sections of the approved product information provided as attachment 1.